Design and structural analysis of novel pharmacophores for potent and selective peroxisome proliferator-activated receptor gamma agonists.

Utilizing medicinal chemistry design strategies such as benzo splitting and ring expansion, we converted PPARalpha/gamma dual agonist 1 to selective PPARgamma agonists 19 and 20. Compounds 19 and 20 were 2- to 4-fold better than rosiglitazone at PPARgamma receptor, with 80- to 100-fold PPARgamma selectivity over PPARalpha receptor. X-ray cocrystal studies in PPARgamma and modeling studies in PPARalpha give molecular insights for the improved PPARgamma potency and selectivity for 19 when compared to 1.

[1]  L. Goossen,et al.  Palladium‐Catalyzed Synthesis of Aryl Ketones from Boronic Acids and Carboxylic Acids Activated in situ by Pivalic Anhydride , 2002 .

[2]  J. Berger,et al.  5-Aryl thiazolidine-2,4-diones: Discovery of PPAR dual α/γ agonists as antidiabetic agents , 2003 .

[3]  Ping-Chiang Lyu,et al.  Structural basis for the structure-activity relationships of peroxisome proliferator-activated receptor agonists. , 2007, Journal of medicinal chemistry.

[4]  P. Sarafidis.  Thiazolidinedione derivatives in diabetes and cardiovascular disease: an update , 2008, Fundamental & clinical pharmacology.

[5]  M. Reilly,et al.  The Metabolic Syndrome: More Than the Sum of Its Parts? , 2003, Circulation.

[6]  5-aryl thiazolidine-2,4-diones: discovery of PPAR dual alpha/gamma agonists as antidiabetic agents. , 2003, Bioorganic & medicinal chemistry letters.

[7]  Ping-Chiang Lyu,et al.  Indol-1-yl acetic acids as peroxisome proliferator-activated receptor agonists: design, synthesis, structural biology, and molecular docking studies. , 2006, Journal of medicinal chemistry.

[8]  I-Lin Lu,et al.  Novel indole-based peroxisome proliferator-activated receptor agonists: design, SAR, structural biology, and biological activities. , 2005, Journal of medicinal chemistry.

[9]  Camille Georges Wermuth,et al.  Application Strategies for the Primary Structure–Activity Relationship Exploration , 2008 .

[10]  T. Willson,et al.  The PPARs: From Orphan Receptors to Drug Discovery , 2000 .

[11]  T. Willson,et al.  Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ , 1998, Nature.

[12]  B. Henke.  Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes. , 2004, Journal of medicinal chemistry.

[13]  C. Wermuth.  APPLICATION STRATEGIES FOR PRIMARY STRUCTURE–ACTIVITY RELATIONSHIP EXPLORATION , 2003 .

[14]  Maria M. Mihaylova,et al.  AMPK and PPARδ Agonists Are Exercise Mimetics , 2008, Cell.